ACM
ENTA icon

AlphaCrest Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

AlphaCrest Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,700
Closed -$555K – 366
2022
Q3 		$555K Buy
+10,700
New +$625K 0.03% 936
2020
Q4 		– Sell
-5,379
Closed -$246K – 1151
2020
Q3 		$246K Buy
+5,379
New +$261K 0.03% 958

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

AlphaCrest Capital Management's ENTA Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2022, closing a stake of 10,700 shares — an estimated $555K sold.

AlphaCrest Capital Management first reported a position in ENTA in Q3 2020 and held it in 2 quarters. The position peaked at $555K in Q3 2022. 147 funds tracked by Wall St. Rank hold ENTA as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 10,700 Enanta Pharmaceuticals shares in Q4 2022, an estimated $555K.
  • AlphaCrest Capital Management first reported a position in Enanta Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • AlphaCrest Capital Management's Enanta Pharmaceuticals position peaked at $555K in Q3 2022.
  • 147 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.